Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 0.79 USD 1.37%
Market Cap: 91.6m USD

Intrinsic Value

CHRS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CHRS stock under the Base Case scenario is 3.65 USD. Compared to the current market price of 0.79 USD, Coherus BioSciences Inc is Undervalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CHRS Intrinsic Value
3.65 USD
Undervaluation 78%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Coherus BioSciences Inc

Valuation History Unavailable

Historical valuation for CHRS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Coherus BioSciences Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Coherus BioSciences Inc

Current Assets 310.2m
Cash & Short-Term Investments 82.4m
Receivables 62.4m
Other Current Assets 165.3m
Non-Current Assets 60.9m
PP&E 2.3m
Intangibles 53m
Other Non-Current Assets 5.7m
Efficiency

Free Cash Flow Analysis
Coherus BioSciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Coherus BioSciences Inc

Revenue
197.5m USD
Cost of Revenue
-85.6m USD
Gross Profit
111.9m USD
Operating Expenses
-216.1m USD
Operating Income
-104.3m USD
Other Expenses
-26.7m USD
Net Income
-130.9m USD
Fundamental Scores

CHRS Profitability Score
Profitability Due Diligence

Coherus BioSciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

34/100
Profitability
Score

Coherus BioSciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

CHRS Solvency Score
Solvency Due Diligence

Coherus BioSciences Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
30/100
Solvency
Score

Coherus BioSciences Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CHRS Price Targets Summary
Coherus BioSciences Inc

Wall Street analysts forecast CHRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CHRS is 5.37 USD with a low forecast of 1.06 USD and a high forecast of 7.35 USD.

Lowest
Price Target
1.06 USD
34% Upside
Average
Price Target
5.37 USD
579% Upside
Highest
Price Target
7.35 USD
830% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Coherus BioSciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CHRS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CHRS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CHRS stock?

The intrinsic value of one CHRS stock under the Base Case scenario is 3.65 USD.

Is CHRS stock undervalued or overvalued?

Compared to the current market price of 0.79 USD, Coherus BioSciences Inc is Undervalued by 78%.

Back to Top